Scientists Find New Way to Predict Kids' Cancer Response

Children with relapsed cancers just got a powerful new tool in their fight for survival, thanks to scientists who discovered a way to predict which patients will benefit from cutting-edge treatment.

Researchers at the University of Birmingham tested a combination therapy on 66 young patients across the UK, France, the Netherlands, and Spain who had cancers that had come back multiple times. These children faced tumors like Ewing sarcoma, brain cancers, and rare bone cancers where cure rates drop below 30% after the disease spreads or returns.

The team combined a common chemotherapy drug with a PARP inhibitor, a DNA repair blocker that works well in adult cancers. They wanted to see if it could help children too.

Twelve patients showed real improvement. Their tumors either shrank partially or completely, or their disease stayed stable for more than six months.

But the real breakthrough came when researchers looked back at the tumors to understand why some kids responded while others didn't. They discovered that children whose tumors had high levels of something called aneuploidy, an abnormal change in the tumor's genetic material, were significantly more likely to benefit from the therapy.

This is the first time aneuploidy score has been linked to treatment response in children's cancer trials. Even better, the high score didn't match specific cancer types but predicted who would respond to this therapy, suggesting it could work across many different childhood cancers.

Dr. Susanne Gatz, who led the study, expressed gratitude to the families who participated. While adults with certain cancers already get personalized treatment based on genetic markers, pediatric oncology hasn't had similar tools until now.

Why This Inspires

This discovery means doctors may soon test tumors for aneuploidy before starting treatment, sparing children from therapies that won't work and getting them faster to ones that will. For families facing the heartbreak of relapsed childhood cancer, having a roadmap feels like hope taking scientific form.

The research team believes this biomarker could extend beyond pediatric cancer to help adults too, multiplying its potential impact across cancer care.

Seventy families said yes to this trial when their children had already fought cancer multiple times, and their courage just opened a door that could help thousands of future patients find the right treatment the first time.